Connaught Laboratories Limited

Aventis Pasteur Limited

Palladin Healthcare International, Inc.

Pasteur Merieux Connaught Canada

Xiaomao Li

Michel Henri Klein

Mary E Ewasyshyn

Suryaprakash Sambhara

Kurt Osterman

Michael H Dosch

Mary E Ewashysyn

Mark Parrington

The present invention is directed to a composition for treating burns. The composition comprises a therapeutically effective amount of one or more weak organic acid compatible with human skin, in a pharmacologically effective carrier delivered at a pH of about 2.5&#x2013;4.5. The weak organic acid is preferably selected from the group consisting of acetic acid, vinegar, citric acid and combinations thereof and the pharmacologically effective carrier is preferably an aqueous based carrier, more preferably a gel form, utilizing a CARBOPOL as a gelling agent. The composition may also include one or more other agents selected from sun blocking agents, skin moisturizing agents, herb extracts and antimicrobial agents.

Composition for pain mediation and apparatus and method of use thereof

Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.

Nucleic acid respiratory syncytial virus vaccines

Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.

A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.

Alphavirus vectors for paramyxovirus vaccines

The present invention is directed to a composition for treating burns. The composition comprises a therapeutically effective amount of one or more weak organic acids compatible with human skin, in a pharmacologically effective carrier delivered at a pH of about 2.5-4.5. The weak organic acid is preferably selected from the group consisting of acetic acid, vinegar, citric acid and combinations thereof and the pharmacologically effective carrier is preferably an aqueous based carrier, more preferably a gel form, utilizing a CARBOPOL as a gelling agent. The composition may also include one or more other agents selected from sun blocking agents, skin moisturizing agents, herb extracts and antimicrobial agents.

Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.

Growing community of inventors

Toronto, Canada

Xiaomao Li